FDA advisory committees meeting from July 13 to take decision on Avandia
GlaxoSmithKline's diabetes pill Avandia will be banned or not, it will be decided during a joint meeting of two FDA advisory committees, which is scheduled on July 13 and 14.
GLAXOSMITHKLINE'S DIABETES pill Avandia will be banned or not, it will be decided during a joint meeting of two FDA advisory committees, which is scheduled on July 13 and 14. The FDA finds itself in a difficult position after reviewing a drug Avandia which was approved a decade ago. GlaxoSmithKline's Avandia is used to help diabetics to control blood sugar that now appears tied to deadly side effects with increased risk of heart attack.
The U.S. Food and Drug Administration (FDA) two-day meeting on July 13 and 14 will help them decide what course of action to take. A panel of outside physicians will consider a range of recommendations including adding more warning labels, limiting which doctors can prescribe the drug and pulling the drug from the market.
According to the GlaxoSmithKline, Avandia is safe and effective when used appropriately. Company also said that we do not believe there is a connection between liver toxicity and this medicine. Diabetes pill Avandia was the second biggest money maker for Glaxo with $2.6 billion in sales in 2006.
In United States, about 20 million people are suffering from Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin. Diabetes medicines make the body more sensitive to insulin to help lower blood sugar.
According to the World Health Organization estimation, 171 million people globally had diabetes in 2000 and projected that number will nearly double by 2030 to 366 million. Diabetes raises the risk of heart disease, stroke, kidney failure and other illnesses.
According to the GlaxoSmithKline, Avandia is safe and effective when used appropriately. Company also said that we do not believe there is a connection between liver toxicity and this medicine. Diabetes pill Avandia was the second biggest money maker for Glaxo with $2.6 billion in sales in 2006.
In United States, about 20 million people are suffering from Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin. Diabetes medicines make the body more sensitive to insulin to help lower blood sugar.
According to the World Health Organization estimation, 171 million people globally had diabetes in 2000 and projected that number will nearly double by 2030 to 366 million. Diabetes raises the risk of heart disease, stroke, kidney failure and other illnesses.
 | Previous Post |
Login
 Login through Social ID
|
Not finding what you are looking for? Search here.
